BLCO — Bausch & Lomb Corp

—
NYSE · Unknown · Unknown · CIK 1860742 ·
Last close
$16.86
Market Cap
$6.02B
52W High
$18.92
52W Low
$13.77
ADV30
382,593
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,394,000,000 867,000,000 108,000,000 -14,000,000 13,859,000,000 367,000,000 7,415,000,000
Mar 2026 1,244,000,000 761,000,000 59,000,000 -71,000,000 13,780,000,000 268,000,000 7,328,000,000
Dec 2025 1,405,000,000 872,000,000 158,000,000 -58,000,000 14,022,000,000 383,000,000 7,503,000,000
Sep 2025 1,281,000,000 771,000,000 80,000,000 -28,000,000 13,832,000,000 310,000,000 7,332,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$458,000,000
Investing CF
$-466,000,000
Financing CF
$118,000,000
CapEx
$-321,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.48
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,016,000,000
Inventory
$999,000,000
Receivables
$1,160,000,000
ST Investments
—
EBIT TTM
$324,000,000
Pretax Income TTM
$-65,000,000
Interest Exp TTM
$389,000,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,324,000,256
EBITDA
$816,000,000
Free Cash Flow
$323,000,000
Enterprise Value
$10,977,100,800
Total Cash
$367,000,000
Total Debt
$5,114,999,808
Shares Out
357,165,246
Trailing EPS
$-0.48
Book Value
$18.09
ROE
-2.5%
ROA
1.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 5,101,000,000 188,000,000 -360,000,000 14,022,000,000 7,503,000,000 6,448,000,000 283,000,000
Dec 2024 4,791,000,000 206,000,000 -317,000,000 13,469,000,000 6,925,000,000 6,473,000,000 232,000,000
Dec 2023 4,146,000,000 204,000,000 -260,000,000 13,442,000,000 6,522,000,000 6,850,000,000 -17,000,000
Dec 2022 3,768,000,000 220,000,000 6,000,000 11,144,000,000 4,043,000,000 7,033,000,000 345,000,000

TTM Snapshot

Revenues TTM
$4,282,000,000
NetIncome TTM
$-310,000,000
OpCashFlow TTM
$0
Assets (Latest)
$14,022,000,000
Forward EPS
$1.11

Max Pain — expiry 2026-10-16

max pain strike: $17.00 · spot: $16.82 · call oi: 2,357 · put oi: 81
Expected Move to 2026-10-16: ±$1.27 (7.58%) — implied range $15.54 – $18.09 · ATM straddle on $17.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CROX Crocs, Inc. $6.05B $126.14 —
ERELY Eregli Demir ve Celik Fabrikalari TAS/ADR $6.05B $9.00 —
LPGCY Laopu Gold Co. Ltd./ADR $6.06B $4.22 —
ST Sensata Technologies Holding plc $6.14B $42.19 —
SLFPY STANDARD LIFE PLC $5.88B $13.13 —

News headlines (Yahoo Finance, 1h cache)

Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026
2026-09-16 22:24 · Yahoo
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
2026-09-11 10:11 · Yahoo
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
2026-09-01 10:58 · Yahoo
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers
2026-08-29 23:06 · Yahoo
3 Healthcare Stocks We Steer Clear Of
2026-08-27 14:33 · Yahoo
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack
2026-08-25 16:54 · Yahoo
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
2026-08-25 15:53 · Yahoo
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
2026-08-25 01:01 · Yahoo
Bausch + Lomb Plans to Advance Dual-Action Eye Drop Targeting Evaporative and Inflammatory Dry Eye Disease to Phase 3
2026-08-24 21:38 · Yahoo
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
2026-08-24 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.